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LETTERS TO THE EDITOR
End-stage silicosis and lung
transplantation: A way forward
Table 1 Lung functional parameters of patients before and
after lung transplant.Before
transplantation
After
transplantation
FVC, % predicted 50.20± 10.8 60.80± 11.4
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∗Silicose em estádio terminal e transplante
pulmonar: Um caminho a seguir
To the Editor:
Lung transplantation is an available and accepted ther-
apy for the management of a wide range of severe lung
disorders.1 Silicosis is a progressive, ﬁbrotic, occupational
lung disease. End-stage silicosis is one of the accepted indi-
cations for lung transplantation, although there is little
published data on this topic.
The aim of our study was to investigate the selection of
recipients and follow-up of lung transplantation for silicosis.
Data from all lung transplant patients with silicosis fol-
lowed at Centro Hospitalar São João between 2008 and 2013,
were retrospectively analyzed.
Six males with a mean age of 55.5± 6.9 years underwent
lung transplantation for silicosis. Of the 6 patients, 3 sub-
jects worked in water exploration wells, 1 was a sandblasting
worker, 1 slate mine worker and 1 quarry worker. At the
time of referral for lung transplant, functional lung charac-
teristics were as follows: FVC 50.20± 10.8% predicted and
FEV1 40.48± 7.9% predicted. The mean pulmonary artery
pressure was 61mm Hg estimated by echocardiography.
Mean time between the ﬁrst observation and lung trans-
plant was 18.5 months. All patients underwent single lung
transplantation, 4 patients underwent left lung transplan-
tation. There was no perioperative mortality, although two
patients developed primary graft dysfunction after trans-
plant. During follow-up, two recipients had cytomegalovirus
infection. All recipients are alive with a mean follow-up time
of 32.8± 17.2 months, with a good quality of life (measured
by the Portuguese version of the Medical Outcomes Study,
Short Form-36,3 presented as the median of the subscales:
physical-function 54.0± 39.1, general health 52.4± 25.7,
vitality 54.0± 19.5, social functioning 70.0± 31.4, mental
health 56.8± 19.9) and improved lung function (Table 1).
Despite the global efforts of prevention, silicosis remains
a worldwide occupational lung disease. There is no proven
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FEV1/FVC ratio 63.47± 17.2 66.38± 11.7
peciﬁc therapy for silicosis2 and this disease can be a lethal
ith poor prognosis. Our study demonstrated that selected
atients with end-stage silicosis can beneﬁt from lung trans-
lantation. This study can also contribute to the current
nowledge about this speciﬁc and rare indication for lung
ransplantation.
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